Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobitolimod in refractory ulcerative colitis
NCT01493960Phase 3Completed
- Sponsor
- InDex Pharmaceuticals
- Start
- Dec 2011
- Primary completion
- Jun 2013
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 7
01
Overview
A Phase 3 trial of cobitolimod in ulcerative colitis (UC), sponsored by InDex Pharmaceuticals. Started Dec 2011; status: completed.
02
Drugs
cobitolimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01493960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01493960.